| abstract |
The invention relates to alkyne compounds of general formula (I), in which groups and residues A, B, W, X, Y, Z, R<1> and R<2> have the meanings as cited in Claim 1. The invention also relates to medicaments containing at least one inventive alkyne. The MCH receptor antagonistic effect renders the inventive medicaments suitable for treating metabolic disorders and/or eating disorders, in particular, obesity, bulimia, anorexia, hyperphagia and diabetes. |